A Phase I, dose-escalating study of safety and pharmacokinetics of inhaled dry powder vancomycin (AeroVanc) in volunteers and patients with cystic fibrosis: a new approach to therapy for methicillin-resistant Staphylococcus aureus.
In conclusion, AeroVanc was well tolerated and achieved high levels in sputum with a mean systemic absorption of 49%, making it a potential therapeutic strategy for respiratory infection with MRSA. PMID: 31964790 [PubMed - as supplied by publisher]
Treatment of pulmonary infections in Cystic Fibrosis (CF) can be challenging due to organisms unique to CF and antibiotic resistance (1). Methicillin Resistant Staphylococcus aureus (MRSA) infections are prevalent in patients with CF and have been associated with poor clinical outcomes. The increasing prevalence of MRSA infections in CF has led to the advent of newer modalities of receiving antibiotics such as inhaled therapies. (2) Inhaled vancomycin is often used in the CF population to treat refractory MRSA infections and has been shown to improve clinical outcomes (2-3).
Publication date: June 2020Source: Journal of Hospital Infection, Volume 105, Issue 2Author(s): J.E. Moore, B.C. Millar
Publication date: Available online 13 April 2020Source: Journal of Hospital InfectionAuthor(s): John E. Moore, B. Cherie Millar
Incidence of and risk factors for chronic lung allograft dysfunction (CLAD) in lung transplantation for cystic fibrosis (CF) are not established. Methicillin resistant staphylococcus aureus (MRSA) is associated with CF morbidity but its association with CLAD is unclear. We aimed to describe CLAD incidence and assess if pre-transplant MRSA colonization is associated with CLAD.
Cystic Fibrosis (CF) is a condition known to have chronic infection of the airways with persistent and excessive inflammation, and abnormally thickened airway secretions leading to bronchiectasis . Persons with CF are preferentially susceptible to certain chronic pathogens such as methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia among others [2 –5]. Nontuberculous mycobacteria (NTM) species have recently risen in significance because of recognition of increased prevalence and perceived pathogenicity [6–10].
ConclusionThere was a significant association of antibiotic therapy and age on S. aureus carriage profiles in CF patients indicating that antibiotic therapy prevents acquisition of new clones, while during aging of patients with persisting S. aureus, dominant clones were selected and mutations in the spa-repeat region accumulated.
This study investigated the impact of a short-term transfer program on clinical markers in an adult CF cohort still being managed by pediatricians. Methods: Clinically relevant data from the year before (T-1), the time of Transfer (T) and the year after the transfer (T+1) were analysed retrospectively. Results: 39 patients (median age 29.0 years; 64% male) were transferred between February and December 2016. Lung function had declined significantly in the year before transfer (in % predicted: Forced Expiratory Volume in 1 second (FEV), 62.8 vs. 57.7, p
Conclusions: S. aureus SAgs belonging to the EGC are highly prevalent in CF clinical isolates. The greater prevalence in these SAgs in CF airway specimens compared to skin isolates suggests that these toxins confer selective advantage in the CF airway.
Conclusions: The pattern of airway colonisation in the Indian setting is different from the Caucasian population, and P. aeruginosa and Burkholderia cepacia complex appear early. Colonisation with P. aeruginosa benefits from therapy. In case of infection, care must be taken while initiating empiric therapy. It should be based on local antibiograms to prevent the emergence of resistant microbes.
Publication date: Available online 11 November 2019Source: The Lancet Respiratory MedicineAuthor(s): Daniel J Wolter, Frankline M Onchiri, Julia Emerson, Mimi R Precit, Michael Lee, Sharon McNamara, Laura Nay, Marcella Blackledge, Ahmet Uluer, David M Orenstein, Michelle Mann, Wynton Hoover, Ronald L Gibson, Jane L Burns, Lucas R Hoffman, Daniel J Wolter, Frankline M Onchiri, Julia Emerson, Mimi R Precit, Michael LeeSummaryBackgroundStaphylococcus aureus is the bacterium cultured most often from respiratory secretions of people with cystic fibrosis. Both meticillin-susceptible S aureus and meticillin-resistant S aureus (MR...